
Samsung Biologics continues to build momentum through expanded manufacturing capabilities and strategic growth across emerging modalities.
The article highlights the company’s latest $262 million manufacturing agreement, alongside its growing global footprint and continued expansion into new areas of biopharmaceutical manufacturing.
Discover how Samsung Biologics is building for continued growth in a rapidly evolving biopharma landscape.

Samsung Biologics continues to build momentum through expanded manufacturing capabilities and strategic growth across emerging modalities.
The article highlights the company’s latest $262 million manufacturing agreement, alongside its growing global footprint and continued expansion into new areas of biopharmaceutical manufacturing.
Discover how Samsung Biologics is building for continued growth in a rapidly evolving biopharma landscape.